Digital Health Startup FareWell Announces Key Hires as it Launches its Enterprise Offering Aimed at Reversing Chronic Disease in the Workplace

Digital Therapeutics to Reverse Chronic Disease

We’ve known what it takes to prevent roughly 80% of all premature death, and the chronic diseases that precede it, for well over 20 years. The focus now must be on how – and FareWell is about how.

FareWell, a startup developing digital therapeutics to treat and reverse diabetes and heart disease, today announced two key additions to its executive team.

Penny Moore and Sachin Kelkar join an esteemed team of leaders and advisors in a San Francisco-based startup focused on reversing chronic disease in the workplace to improve the health of American workers and competitiveness of their employers.

Penny Moore joins FareWell as Head of Enterprise. Penny is an accomplished growth strategist who served as Chief Growth Officer at Kurbo Health, focused on childhood obesity, and ShapeUp, which delivered social wellness programs to employers and insurance companies around the world, before being acquired by Virgin Pulse in 2016. She also held leadership roles at Kaiser Permanente, UnitedHealthcare, and Aetna. Penny received a B.S. Pharmacy degree from the University of Missouri-Kansas City and a Certified Health Insurance Executive (CHIE) accreditation from AHIP.

Sachin Kelkar joins FareWell as Head of Finance and Corporate Development. Sachin is a seasoned finance and corporate development executive, most recently serving as Senior Vice President of Strategy and Corporate Development at Practice Fusion. Sachin fostered his passion to transform healthcare as Co-founder of LifeTech Capital, an advisory firm focused on bringing innovative biotech and medtech companies to market. He holds a B.A. from UC Berkeley and an MBA from the University of Chicago Booth School of Business.

“Penny and Sachin are excellent additions to our team. They are passionate about our mission to treat and reverse chronic disease, and they have unique experiences and key relationships to help us build and accelerate growth,” said CEO and Co-founder Kevin Appelbaum. “As we lead the second wave of innovation in digital therapeutics – focusing on disease reversal – FareWell will continue to attract and add more exceptional members to the team.”

FareWell’s Vision and Visionaries

Read the full article from the Source…

Leave a Reply

Your email address will not be published. Required fields are marked *